Incyte Reports Strong Q1 2026 Earnings with Revenue Growth and Pipeline Progress

Incyte reported a 21% increase in Q1 2026 revenue to $1.27 billion and a 20% rise in net sales to $1.1 billion, driven by strong demand across its commercial portfolio. The company also highlighted positive phase III trial results for povorcitinib in nonsegmental vitiligo and regulatory progress for its HS filing.

By MarketBeat Tue, April 28, 2026 at 5:17 PM GMT+3 9 min read · Yahoo Finance · April 28, 2026, 14:17 UTC

Incyte Reports Strong Q1 2026 Earnings with Revenue Growth and Pipeline Progress

Tickers: $INCY

Topics: Earnings FDA Approval Pipeline Development Revenue Growth Stock Performance

Read the full article at Yahoo Finance

More World news

Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC